Setmelanotide was initially FDA-approved in 2020 for chronic weight management in individuals six years or older with obesity caused by POMC deficiency, proprotein subtilisin/kexin type 1 (PCSK1), or LEPR deficiency [46]. Here, PCSK1 is linked to hyperinsulinemic hypoglycemia, familial, 4.